PharmacyCodes



Zafirlukast en es it fr

Categoria

Zafirlukast Nombres de marca, Zafirlukast Analogos

Zafirlukast Marca los nombres de mezcla

  • No information avaliable

    • Zafirlukast Formula quimica

    C31H33N3O6S

    Zafirlukast RX enlace

    http://www.rxlist.com/cgi/generic/zafirlukast.htm

    Zafirlukast FDA hoja

    Zafirlukast FDA

    Zafirlukast MSDS (hoja de seguridad de materiales)

    Zafirlukast MSDS

    Zafirlukast Sintesis de referencia

    FJ Brown et al. Eur. pat. Appl. 199543, PR Bernstein et al, Patente de EE.UU... 4.859.692 (1986, 1989, tanto a ICI)

    Zafirlukast Peso molecular

    575.676 g/mol

    Zafirlukast Punto de fusion

    139 oC

    Zafirlukast H2O Solubilidad

    No hay información disponible

    Zafirlukast Estado

    Solid

    Zafirlukast LogP

    5.787

    Zafirlukast Formas de dosificacion

    Tableta

    Zafirlukast Indicacion

    Para la profilaxis y tratamiento crónico del asma.

    Zafirlukast Farmacologia

    Zafirlukast es un sintético, leucotrienos selectivo antagonista del receptor péptido (ARLT) indicado para la profilaxis y el tratamiento crónico del asma. Los pacientes con asma se encontraron en un estudio en 25 - 100 veces más sensibles a la actividad broncoconstrictores del LTD4 inhalado que los sujetos no asmáticos. En estudios in vitro han demostrado que zafirlukast antagonizado la actividad contráctil de los tres leucotrienos (LTC4, LTD4 y LTE4) en la realización de músculo liso bronquial de los animales de laboratorio y seres humanos. Zafirlukast impedido intradérmica LTD4 inducida por el aumento de la permeabilidad vascular cutánea e inhibe la inhalación de LTD4 inducida por la afluencia de eosinófilos en los pulmones del animal.

    Zafirlukast Absorcion

    Absorbe rápidamente tras su administración oral, reduce tras una comida rica en grasa o proteínas.

    Zafirlukast Toxicidad

    Los efectos secundarios incluyen sarpullido y malestar estomacal.

    Zafirlukast Informacion de Pacientes

    Patients should be told that a rare side effect of ACCOLATE is hepatic dysfunction, and to contact their physician immediately if they experience symptoms of hepatic dysfunction (eg. right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, and anorexia). Liver failure resulting in liver transplantation and death has occurred in patients taking zafirlukast .

    ACCOLATE is indicated for the chronic treatment of asthma and should be taken regularly as prescribed, even during symptom-free periods. ACCOLATE is not a bronchodilator and should not be used to treat acute episodes of asthma. Patients receiving ACCOLATE should be instructed not to decrease the dose or stop taking any other antiasthma medications unless instructed by a physician. Women who are breast-feeding should be instructed not to take ACCOLATE. Alternative antiasthma medication should be considered in such patients.

    The bioavailability of ACCOLATE may be decreased when taken with food. Patients should be instructed to take ACCOLATE at least 1 hour before or 2 hours after meals.

    Eosinophilic Conditions: In rare cases, patients on ACCOLATE therapy may present with systemic eosinophilia, eosinophilic pneumonia, or clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic steroid therapy. These events usually, but not always, have been associated with the reduction of oral steroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between ACCOLATE and these underlying conditions has not been established .

    Zafirlukast Organismos afectados

    Humanos y otros mamíferos